Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem^® Clinical Programs in Japan

Athersys, Inc. announced that its partner, HEALIOS K.K. provided updates on its two clinical programs evaluating MultiStem® cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome in Japan on an exclusive basis.